Pharmaceuticals, Biotechnology and Life Sciences
Exscientia provided Tuesday an update on its pipeline prioritisation strategy designed to further strengthen the Company’s focus, investment and infrastructure on programmes of greatest potential for differentiation and value creation, outlinging strategy which will support continued investment into market-leading technology while maintaining cash runway well into 2026.
Exscientia plc (Nasdaq: EXAI) has the appointed Michael Krams, M.D., as its Chief Quantitative Medicine Officer, to lead clinical development strategy for Exscientia’s portfolio of investigational medicines.
Exscientia and the University of Oxford Target Discovery Institute (Oxford TDI) have announced the formation of Xcellomics – a program designed to source cellular functional assays from the global academic community to develop novel screens and identify targets and therapeutic candidates for unmet medical needs.